Skip to main content
NCBI home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 2002;113:21–30.

Recombinant thyrotropin for detection of recurrent thyroid cancer.

Paul W Ladenson 1
PMCID: PMC2194483  PMID: 12053710

Abstract

Detection of recurrent thyroid cancer tumor requires TSH stimulation for radioiodine scanning and thyroglobulin (Tg) measurement. Temporary thyroid hormone withdrawal has previously been used, but causes hypothyroidism and, rarely, tumor progression. METHODS: The alternative of recombinant thyrotropin (rTSH) was assessed in two randomized clinical trials in which patients had 131I and Tg testing twice: first after rTSH, and second after thyroid hormone withdrawal. Test results and quality of life were compared. RESULTS: In the first trial, among 62 of 127 patients with positive scans, rTSH was equivalent to withdrawal in 41, superior in 3, and inferior in 18 (P < 0.05), suggesting a lesser sensitivity of rTSH scans. In a second trial employing enhanced techniques, among 108 of 220 patients with positive scans, there was no difference in the number of superior rTSH and withdrawal scans. Furthermore, among all patients with withdrawal study evidence of residual thyroid tissue, 74% of all patients with residual thyroid tissue and 100% of patients with tumor metastases had rTSH-stimulated thyroglobulin values above 2 ng/mL. Naturally, patients experienced significantly more symptoms and diminished quality of life when hypothyroid than after rhTSH. CONCLUSIONS: Combined rTSH-stimulated radioiodine and Tg testing is as sensitive as thyroid hormone withdrawal to detect recurrent thyroid cancer, and causes less morbidity.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrecht R. R., Ewing S. J. Standardizing the administration of the Profile of Mood States (POMS): development of alternative word lists. J Pers Assess. 1989 Spring;53(1):31–39. doi: 10.1207/s15327752jpa5301_4. [DOI] [PubMed] [Google Scholar]
  2. Billewicz W. Z., Chapman R. S., Crooks J., Day M. E., Gossage J., Wayne E., Young J. A. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med. 1969 Apr;38(150):255–266. [PubMed] [Google Scholar]
  3. Braverman L. E., Pratt B. M., Ebner S., Longcope C. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab. 1992 May;74(5):1135–1139. doi: 10.1210/jcem.74.5.1569160. [DOI] [PubMed] [Google Scholar]
  4. Goldberg L. D., Ditchek N. T. Thyroid carcinoma with spinal cord compression. JAMA. 1981 Mar 6;245(9):953–954. [PubMed] [Google Scholar]
  5. Goldman J. M., Line B. R., Aamodt R. L., Robbins J. Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab. 1980 Apr;50(4):734–739. doi: 10.1210/jcem-50-4-734. [DOI] [PubMed] [Google Scholar]
  6. Haugen B. R., Pacini F., Reiners C., Schlumberger M., Ladenson P. W., Sherman S. I., Cooper D. S., Graham K. E., Braverman L. E., Skarulis M. C. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov;84(11):3877–3885. doi: 10.1210/jcem.84.11.6094. [DOI] [PubMed] [Google Scholar]
  7. Huber G. K., Fong P., Concepcion E. S., Davies T. F. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab. 1991 Jun;72(6):1328–1331. doi: 10.1210/jcem-72-6-1328. [DOI] [PubMed] [Google Scholar]
  8. Krishnamurthy G. T. Human reaction to bovine TSH: concise communication. J Nucl Med. 1978 Mar;19(3):284–286. [PubMed] [Google Scholar]
  9. Ladenson P. W., Braverman L. E., Mazzaferri E. L., Brucker-Davis F., Cooper D. S., Garber J. R., Wondisford F. E., Davies T. F., DeGroot L. J., Daniels G. H. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997 Sep 25;337(13):888–896. doi: 10.1056/NEJM199709253371304. [DOI] [PubMed] [Google Scholar]
  10. Law A., Jack G. W., Tellez M., Edmonds C. J. In-vivo studies of a human-thyrotrophin preparation. J Endocrinol. 1986 Aug;110(2):375–378. doi: 10.1677/joe.0.1100375. [DOI] [PubMed] [Google Scholar]
  11. MALOOF F., VICKERY A. L., RAPP B. An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I 131. J Clin Endocrinol Metab. 1956 Jan;16(1):1–27. doi: 10.1210/jcem-16-1-1. [DOI] [PubMed] [Google Scholar]
  12. Maxon H. R., 3rd, Smith H. S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990 Sep;19(3):685–718. [PubMed] [Google Scholar]
  13. Mazzaferri E. L., Jhiang S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994 Nov;97(5):418–428. doi: 10.1016/0002-9343(94)90321-2. [DOI] [PubMed] [Google Scholar]
  14. Melmed S., Harada A., Hershman J. M., Krishnamurthy G. T., Blahd W. H. Neutralizing antibodies to bovine thyrotropin in immunized patients with thyroid cancer. J Clin Endocrinol Metab. 1980 Aug;51(2):358–363. doi: 10.1210/jcem-51-2-358. [DOI] [PubMed] [Google Scholar]
  15. Ozata M., Suzuki S., Miyamoto T., Liu R. T., Fierro-Renoy F., DeGroot L. J. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. 1994 Jul;79(1):98–105. doi: 10.1210/jcem.79.1.8027262. [DOI] [PubMed] [Google Scholar]
  16. Pacini F., Pinchera A., Giani C., Grasso L., Baschieri L. Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf) 1980 Jul;13(1):107–110. doi: 10.1111/j.1365-2265.1980.tb01030.x. [DOI] [PubMed] [Google Scholar]
  17. Ringel M. D., Ladenson P. W. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab. 1996 May;81(5):1724–1725. doi: 10.1210/jcem.81.5.8626823. [DOI] [PubMed] [Google Scholar]
  18. Robbins J., Merino M. J., Boice J. D., Jr, Ron E., Ain K. B., Alexander H. R., Norton J. A., Reynolds J. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med. 1991 Jul 15;115(2):133–147. doi: 10.7326/0003-4819-115-2-133. [DOI] [PubMed] [Google Scholar]
  19. SHERMAN W. B., WERNER S. C. GENERALIZED ALLERGIC REACTION TO BOVINE THYROTROPIN. JAMA. 1964 Oct 19;190:244–245. doi: 10.1001/jama.1964.03070160068023. [DOI] [PubMed] [Google Scholar]
  20. STURGEON C. T., DAVIS F. E., CATZ B., PETIT D., STARR P. Treatment of thyroid cancer metastases with TSH and I131 during thyroid hormone medication. J Clin Endocrinol Metab. 1953 Nov;13(11):1391–1407. doi: 10.1210/jcem-13-11-1391. [DOI] [PubMed] [Google Scholar]
  21. Schneider A. B., Line B. R., Goldman J. M., Robbins J. Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab. 1981 Dec;53(6):1199–1206. doi: 10.1210/jcem-53-6-1199. [DOI] [PubMed] [Google Scholar]
  22. Sfakianakis G. N., Skillman T. G., George J. M. Thyroxine withdrawal in thyroid cancer. Ohio State Med J. 1975 Feb;71(2):79–82. [PubMed] [Google Scholar]
  23. Sherman S. I., Brierley J. D., Sperling M., Ain K. B., Bigos S. T., Cooper D. S., Haugen B. R., Ho M., Klein I., Ladenson P. W. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998 Sep 1;83(5):1012–1021. doi: 10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  24. Szkudlinski M. W., Thotakura N. R., Bucci I., Joshi L. R., Tsai A., East-Palmer J., Shiloach J., Weintraub B. D. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology. 1993 Oct;133(4):1490–1503. doi: 10.1210/endo.133.4.8404588. [DOI] [PubMed] [Google Scholar]
  25. Weintraub B. D., Szkudlinski M. W. Development and in vitro characterization of human recombinant thyrotropin. Thyroid. 1999 May;9(5):447–450. doi: 10.1089/thy.1999.9.447. [DOI] [PubMed] [Google Scholar]
  26. Weintraub B. D., Wondisford F. E., Farr E. A., Steinfelder H. J., Radovick S., Gesundheit N., Gyves P. W., Taylor T., DeCherney G. S. Pre-translational and post-translational regulation of TSH: relationship to bioactivity. Horm Metab Res Suppl. 1990;23:9–11. [PubMed] [Google Scholar]
  27. Wondisford F. E., Radovick S., Moates J. M., Usala S. J., Weintraub B. D. Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem. 1988 Sep 5;263(25):12538–12542. [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES